

11/03/2008,10521159II.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTASXY1626

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 12:57:24 ON 25 FEB 2008
FILE 'CAPLUS' ENTERED AT 12:57:24 ON 25 FEB 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	153.08	972.15
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-22.40	-35.20

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	153.08	972.15
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-22.40	-35.20

FILE 'REGISTRY' ENTERED AT 12:57:33 ON 25 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 24 FEB 2008 HIGHEST RN 1005323-41-0
DICTIONARY FILE UPDATES: 24 FEB 2008 HIGHEST RN 1005323-41-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

11/03/2008,10521159II.trn

=>

Uploading C:\Program Files\Stnexp\Queries\10521159II.str



chain nodes :

7 8 9 10 11 12 19

ring nodes :

1 2 3 4 5 6 13 14 15 16 17 18

chain bonds :

5-7 7-8 7-19 8-9 9-10 9-11 10-12 12-13

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18

exact/norm bonds :

7-19 9-10 9-11 10-12

exact bonds :

5-7 7-8 8-9 12-13

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom

L23 STRUCTURE UPLOADED

=> d 123

L23 HAS NO ANSWERS

L23 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 123

11/03/2008,10521159II.trn

SAMPLE SEARCH INITIATED 12:57:50 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 4055 TO ITERATE

49.3% PROCESSED 2000 ITERATIONS 7 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 77281 TO 84919
PROJECTED ANSWERS: 57 TO 509

L24 7 SEA SSS SAM L23

=> s 123 full
FULL SEARCH INITIATED 12:57:54 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 79509 TO ITERATE

100.0% PROCESSED 79509 ITERATIONS 387 ANSWERS
SEARCH TIME: 00.00.01

L25 387 SEA SSS FUL L23

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	178.36	1150.51
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-35.20

FILE 'CAPLUS' ENTERED AT 12:58:00 ON 25 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Feb 2008 VOL 148 ISS 9
FILE LAST UPDATED: 24 Feb 2008 (20080224/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 125

11/03/2008,10521159II.trn


L26 17 L25

=> d ed abs ibib hitstr tot

11/03/2008,10521159II.trn

L26 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 ED Entered STN: 08 May 2006
 AB Enantioselective addns. of pyrroles to α,β -unsatd. 2-acyl imidazoles catalyzed by a bis(oxazoliny)pyridine-scandium(III) triflate complex have been accomplished. The α,β -unsatd. 2-acyl imidazoles were synthesized in high yields through Wittig olefination. A short, enantioselective synthesis of the alkaloid (+)-heliotridane has been accomplished utilizing this methodol. and a 2-acyl imidazole cleavage and cyclization. This methodol. was then extended to the one-pot asym. synthesis of 2-substituted indoles.
 ACCESSION NUMBER: 2006:427406 CAPLUS
 DOCUMENT NUMBER: 145:103608
 TITLE: Catalytic Enantioselective Pyrrole Alkylations of α,β -Unsaturated 2-Acyl Imidazoles
 AUTHOR(S): Evans, David A.; Fandrick, Keith R.
 CORPORATE SOURCE: Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, 02138, USA
 SOURCE: Organic Letters (2006), 8(11), 2249-2252
 CODEN: ORLEF7; ISSN: 1523-7060
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 896464-91-8P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (enantioselective addns. of pyrroles and indoles to α,β -unsatd. 2-acyl imidazoles catalyzed by a bis(oxazoliny)pyridine-scandium(III) triflate complex)
 RN 896464-91-8 CAPLUS
 CN 1H-Indole-2-propanamide, β -phenyl-N-[(1R)-1-phenylethyl]-, (β S)-(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT



L26 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 thioalkoxy, or C1--4 perfluoroalkyl(oxy), etc.; and the pharmaceutically acceptable salts, solvates, active metabolites, or prodrug thereof are claimed in this invention. The compds. in this invention were tested in vitro for their activity against factor Xla, factor Xa and thrombin. The inhibition data (IC50) were detd. from the assay. Invention compd. II showed IC50 values of 0.87 μ M for factor Xla, 82 μ M for factor Xa, and 4.3 μ M for thrombin.

ACCESSION NUMBER: 2006:100022 CAPLUS
 DOCUMENT NUMBER: 144:164251
 TITLE: Indole derivatives and their pharmaceutical compositions and methods for treatment of thrombosis
 INVENTOR(S): Deng, Hongfeng; Lin, Jian; Guo, Zihong; Meyers, Harold
 PATENT ASSIGNEE(S): Daiamed, Inc., USA
 SOURCE: PCT Int. Appl., 166 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006012504	A2	20060202	WO 2005-US26022	20050722
WO 2006012504	A3	20060518		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1773771	A2	20070418	EP 2005-775564	20050722
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
PRIORITY APPLN. INFO.:		US 2004-590718P	P	20040723
		WO 2005-US26022	W	20050722


OTHER SOURCE(S): MARPAT 144:164251
 IT 874757-20-7 874757-27-4
 RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (indole derivs. and their methods for treatment of thrombosis)
 RN 874757-20-7 CAPLUS
 CN 1H-Indole-1-propanamide, 3-(aminoininomethyl)-N-[(4-methoxyphenyl)methyl]- β -phenyl- (CA INDEX NAME)

L26 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 ED Entered STN: 03 Feb 2006
 GI




AB The invention provides compds. of formula I, pharmaceutical compns., and methods for the treatment of thromboembolic disorders, such as, for example, arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, or thromboembolic disorders in the chambers of the heart. Compds. of formula I wherein W is N or CR6, where R6 is H, halo, OH, (un)substituted C1-6 alkyl, C2-6 alkenyl, C1-6 alkoxy, or C2-6 alkoxyalkyl, etc.; X1 is (H,H) or NR7, where R7 is H, alkyl, OH, NH2, NO2, CO2R7a, where R7a is C1-6 alkyl, or R7R7a together forms a 5- to 6-membered ring, etc.; Y is NH or O; R1 is (un)substituted C2-7 alkanoyl, C1-6 alkyl, C2-6 alkenyl, C1-6 alkoxy, or C2-12 alkoxyalkyl, etc.; R2 is H, OH, (un)substituted C1-6 alkyl, C2-6 alkenyl, C1-6 alkoxy, C7-16 aralkoxy, CF3, halo, amidino, N-hydroxyamidino, or guanidino, etc.; R3 is H, or C1-6 alkyl, or R3R5 or R3R7 together form a 5- to 6-membered ring, etc.; R4 is H, (un)substituted C2-7 alkanoyl, C1-6 (amino)alkyl, C2-6 alkenyl, C2-12 alkoxyalkyl, C2-12 alkylsulfonyl, C6 or C10 arum, C7-16 arylalkyl, C7 or C11 aroyl, C1-6 azidoalkyl, carboxaldehyde, carboxamide, etc.; R5 is H, (un)substituted C1-6 alkyl, C2-6 alkenyl, C1-6 alkoxy, carboxamide, C3-8 cycloalkyl, Oh, NO2, CN,
 C1-6

L26 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 874757-27-4 CAPLUS
 CN 1H-Indole-1-propanamide, 3-(aminoininomethyl)- β -phenyl-N-(phenylmethyl)- (CA INDEX NAME)



11/03/2008,10521159II.trn

L26 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ED Entered STN: 13 Nov 2005
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The unusual [5.3.2]-bicyclic structure of the insecticidal Amaryllidaceae alkaloids cripowellin A (1) and B (2) has been synthesized for the first time via a sequence of Sharpless dihydroxylation, ring-closing metathesis, and intramol. Heck reaction. The asym. synthesis of the 1-epi-aglycon I proceeds with virtually complete diastereo- and enantioselectivity (de, ee \geq 98%) in 13 steps and an overall yield of 5.6%. In addition, three alternative approaches toward the aglycon II are also described focusing on (1) the alkylation of the 2-benzazepinedithianes III (R = PhCH₂, 4-MeC₆H₄SO₂) with the electrophile IV, (2) a radical cyclization of the precursor (R/S,S,S)-V, and (3) an intramol. arylation reaction of the aryl ketone VI.

ACCESSION NUMBER: 2005:1203518 CAPLUS
DOCUMENT NUMBER: 144:108485
TITLE: Asymmetric Total Synthesis of the 1-epi-Aglycon of the cripowellins A and B
AUTHOR(S): Enders, Dieter; Lenzen, Achim; Backes, Michael; Janeck, Carsten; Catlin, Kelly; Lannou, Marie-Isabelle; Runsink, Jan; Raabe, Gerhard
CORPORATE SOURCE: Institut fuer Organische Chemie, RWTH Aachen, Aachen, 52074, Germany
SOURCE: Journal of Organic Chemistry (2005), 70 (25), 10538-10551
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:108485
IT 872832-20-7P 872832-21-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(asym. total synthesis of 1-epi-aglycon of cripowellins A and B via Sharpless dihydroxylation, ring-closing metathesis, and intramol. Heck reaction)
RN 872832-20-7 CAPLUS
CN 1,3-Benzodioxole-5-propanamide, β -1,3-dithian-2-yl-N-(phenylmethyl)-, (β S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

L26 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 872832-21-8 CAPLUS
CN 1,3-Benzodioxole-5-propanamide, β -1,3-dithian-2-yl-N-(phenylmethyl)-, (β R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




REFERENCE COUNT: 122 THERE ARE 122 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ED Entered STN: 09 May 2005

AB Fused and non-fused N-heterocyclic compds. undergo conjugate addition to unsatd. imides and enones in the presence of a chiral [(salen)Al(III)] complex with generally high enantioselectivity.


ACCESSION NUMBER: 2005:390717 CAPLUS
DOCUMENT NUMBER: 143:78164
TITLE: Highly enantioselective catalytic conjugate addition of N-heterocycles to α,β -unsaturated ketones and imides
AUTHOR(S): Gandelman, Mark; Jacobsen, Eric N.
CORPORATE SOURCE: Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, 02138, USA
SOURCE: Angewandte Chemie, International Edition (2005), 44 (16), 2393-2397
CODEN: ACHIEP5; ISSN: 1433-7851
PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:78164
IT 855317-44-1P
RL: BYP (Byproduct); PREP (Preparation)
(study of aluminum-catalyzed stereoselective catalytic conjugate addition of benzotriazole to α,β -unsatd. amides)
RN 855317-44-1 CAPLUS
CN 1H-Benzotriazole-2-propanamide, N-benzoyl- β -phenyl-, (β R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 855317-39-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(study of aluminum-catalyzed stereoselective catalytic conjugate addition of benzotriazole to α,β -unsatd. amides)
RN 855317-39-4 CAPLUS
CN 2H-Benzotriazole-2-propanamide, N-benzoyl- β -phenyl-, (β R)- (CA INDEX NAME)

Absolute stereochemistry.




L26 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


Young, Shawquia, Page 7

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 645380-33-2 CAPLUS
CN 4-Piperidinepropanamide,
N-[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-
4-fluoro- β -(4-fluorophenyl)-N-methyl-, (BR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 645380-37-6 CAPLUS
CN 4-Piperidinepropanamide,
N-[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-
4-fluoro- β -(4-fluorophenyl)-N-methyl-, (BS)- (CA INDEX NAME)


Absolute stereochemistry.

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 645380-41-2 CAPLUS
CN 4-Piperidinepropanamide, N-[(3,5-dibromophenyl)methyl]-4-fluoro- β -(4-fluorophenyl)-N-methyl-, (β R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 645380-43-4 CAPLUS
CN 4-Piperidinepropanamide, N-[(3,5-dibromophenyl)methyl]-4-fluoro- β -(4-fluorophenyl)-N-methyl-, (β S)- (CA INDEX NAME)


Absolute stereochemistry.

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 645380-49-0 CAPLUS
CN 4-Piperidinepropanamide,
N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-
β-(2,4-dichlorophenyl)-4-fluoro-N-methyl-, (βR)- (CA INDEX
NAME)


Absolute stereochemistry.



RN 645380-53-6 CAPLUS
CN 4-Piperidinepropanamide,
N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-
 β -(2,4-dichlorophenyl)-4-fluoro-N-methyl-, (β S)- (CA INDEX
NAME)


Absolute stereochemistry.

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 645380-55-8 CAPLUS
CN 4-Piperidinepropanamide,
N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-
4-fluoro- β -(4-fluoro-2-methylphenyl)-N-methyl-, (β R)- (CA INDEX
NAME)

Absolute stereochemistry.




RN 645380-59-2 CAPLUS
CN 4-Piperidinepropanamide,
N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-
4-fluoro- β -(4-fluoro-2-methylphenyl)-N-methyl-, (β S)- (CA INDEX
NAME)

Absolute stereochemistry.


11/03/2008,10521159II.trn

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 645380-75-2 CAPLUS
CN 4-Piperidinepropanamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-fluoro-β-(4-fluorophenyl)-N-methyl-, (βR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 645380-77-4 CAPLUS
CN 4-Piperidinepropanamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-fluoro-β-(4-fluorophenyl)-N-methyl-, (βS)- (CA INDEX NAME)


Absolute stereochemistry.

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 645381-01-7 CAPLUS
CN 4-Pyridinepropanamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-β-(4-fluoro-2-methylphenyl)-1,2,3,6-tetrahydro-N-methyl-, (βR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 645381-03-9 CAPLUS
CN 4-Pyridinepropanamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-β-(4-fluoro-2-methylphenyl)-1,2,3,6-tetrahydro-N-methyl-, (βS)- (CA INDEX NAME)


Absolute stereochemistry.

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 645380-83-2 CAPLUS
CN 4-Piperidinepropanamide, β-(4-chlorophenyl)-N-[(3,5-dibromophenyl)methyl]-4-fluoro-N-methyl-, (βR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 645380-85-4 CAPLUS
CN 4-Piperidinepropanamide, β-(4-chlorophenyl)-N-[(3,5-dibromophenyl)methyl]-4-fluoro-N-methyl-, (βS)- (CA INDEX NAME)


Absolute stereochemistry.

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 645381-08-4 CAPLUS
CN 2-Morpholinepropanamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-β-(4-fluorophenyl)-N-methyl-, (βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 645381-10-8 CAPLUS
CN 2-Morpholinepropanamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-β-(4-fluorophenyl)-N-methyl-, (βR,2S)- (CA INDEX NAME)

Absolute stereochemistry.


11/03/2008,10521159II.trn

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 645381-12-0 CAPLUS
CN 2-Morpholinepropanamide,
N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-
β-(4-fluorophenyl)-N-methyl-, (βS,2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 645381-14-2 CAPLUS
CN 2-Morpholinepropanamide,
N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-
β-(4-fluorophenyl)-N-methyl-, (βS,2S)- (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 645379-91-5P, (R)-N-(3,5-Dichlorobenzyl)-3-(4-fluorophenyl)-N-methyl-3-piperidin-4-ylpropionamide 645379-92-6P, (S)-N-(3,5-Dichlorobenzyl)-3-(4-fluorophenyl)-N-methyl-3-piperidin-4-ylpropionamide 645379-94-8P, (3R)-N-[(1R)-1-(3,5-Dichlorophenyl)ethyl]-3-(4-fluorophenyl)-N-methyl-3-(piperidin-4-yl)propionamide 645379-95-9P, (3R)-N-[(1S)-1-(3,5-Dichlorophenyl)ethyl]-3-(4-fluorophenyl)-N-methyl-3-(piperidin-4-yl)propionamide 645379-96-0P, (3S)-N-[(1R)-1-(3,5-Dichlorophenyl)ethyl]-3-(4-fluorophenyl)-N-methyl-3-(piperidin-4-yl)propionamide 645379-97-1P, (3S)-N-[(1S)-1-(3,5-Dichlorophenyl)ethyl]-3-(4-fluorophenyl)-N-methyl-3-(piperidin-4-yl)propionamide 645380-03-6P 645380-04-7P 645380-08-1P 645380-09-2P 645380-10-5P,

(3R)-N-[(1S)-1-[3,5-Bis(trifluoromethyl)phenyl]ethyl]-3-(4-fluorophenyl)-N-methyl-3-(4-piperidinyl)propionamide 645380-11-6P,

(3S)-N-[(1S)-1-[3,5-Bis(trifluoromethyl)phenyl]ethyl]-3-(4-fluorophenyl)-N-methyl-3-(4-piperidinyl)propionamide 645380-67-2P 645380-69-4P 645380-71-8P, (R)-N-[(3,5-

Dibromophenyl)methyl]-3-(3,4-dichlorophenyl)-3-(4-fluoro-4-piperidinyl)-N-methylpropionamide 645380-73-0P, (S)-N-[(3,5-

Dibromophenyl)methyl]-3-(3,4-dichlorophenyl)-3-(4-fluoro-4-piperidinyl)-N-methylpropionamide

RI: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(N-benzyl-3-Ph-3-heterocyclyl-propionamide compds. as tachykinin

and/or


serotonin reuptake inhibitors)

RN 645379-91-5 CAPLUS

CN 4-Piperidinepropanamide, N-[(3,5-dichlorophenyl)methyl]-β-(4-fluorophenyl)-N-methyl-, (βR)- (CA INDEX NAME)


Absolute stereochemistry.

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 645379-92-6 CAPLUS
CN 4-Piperidinepropanamide, N-[(3,5-dichlorophenyl)methyl]-β-(4-fluorophenyl)-N-methyl-, (βS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 645379-94-8 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-1-(3,5-dichlorophenyl)ethyl]-β-(4-fluorophenyl)-N-methyl-, (βR)- (CA INDEX NAME)


Absolute stereochemistry.

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 645379-95-9 CAPLUS
CN 4-Piperidinepropanamide, N-[(1S)-1-(3,5-dichlorophenyl)ethyl]-β-(4-fluorophenyl)-N-methyl-, (βR)- (CA INDEX NAME)

Absolute stereochemistry.




RN 645379-96-0 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-1-(3,5-dichlorophenyl)ethyl]-β-(4-fluorophenyl)-N-methyl-, (βS)- (CA INDEX NAME)

Absolute stereochemistry.


11/03/2008,10521159II.trn

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 645379-97-1 CAPLUS
CN 4-Piperidinepropanamide, N-[(1S)-1-(3,5-dichlorophenyl)ethyl]-β-(4-fluorophenyl)-N-methyl-, (βS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 645380-03-6 CAPLUS
CN 4-Piperidinepropanamide, N-[(3,5-dichlorophenyl)methyl]-4-fluoro-β-(4-fluorophenyl)-N-methyl-, monohydrochloride, (βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 645380-09-2 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-β-(4-fluorophenyl)-N-methyl-, monohydrochloride, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 645380-10-5 CAPLUS
CN 4-Piperidinepropanamide, N-[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-β-(4-fluorophenyl)-N-methyl-, (βR)- (CA INDEX NAME)


Absolute stereochemistry.

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 645380-04-7 CAPLUS
CN 4-Piperidinepropanamide, N-[(3,5-dichlorophenyl)methyl]-4-fluoro-β-(4-fluorophenyl)-N-methyl-, monohydrochloride, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645380-08-1 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-β-(4-fluorophenyl)-N-methyl-, monohydrochloride, (βR)- (9CI) (CA INDEX NAME)

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 645380-11-6 CAPLUS
CN 4-Piperidinepropanamide, N-[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-β-(4-fluorophenyl)-N-methyl-, (βS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 645380-67-2 CAPLUS
CN 4-Piperidinepropanamide, N-[(3,5-dibromophenyl)methyl]-4-fluoro-β-(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride, (βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

11/03/2008,10521159II.trn


L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 645380-69-4 CAPLUS
CN 4-Piperidinepropanamide, N-[(3,5-dibromophenyl)methyl]-4-fluoro- β -(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride, (β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(4-fluorophenyl)-N-methyl-3-piperidin-4-ylpropionamide 645379-99-3P, N-(3,5-Dichlorobenzyl)-3-(4-fluorophenyl)-3-(4-fluoropiperidin-4-yl)-N-methylpropionamide 645380-06-9P, N-[(3,5-Bis(trifluoromethyl)phenyl)methyl]-3-(4-fluorophenyl)-N-methyl-3-[1-(2-methoxyethyl)-4-piperidinyl]propionamide 645380-65-0P, N-[(3,5-Dibromophenyl)methyl]-3-(4-fluoro-2-methylphenyl)-3-(4-fluoro-4-piperidinyl)-N-methylpropionamide hydrochloride 645381-06-2P,


N-[(3,5-Bis(trifluoromethyl)phenyl)methyl]-3-(4-fluorophenyl)-3-(3-fluoro-3-piperidinyl)-N-methylpropionamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(N-benzyl-3-Ph-3-heterocyclyl-propionamide compds. as tachykinin

and/or serotonin reuptake inhibitors)

RN 645379-89-1 CAPLUS
CN 4-Piperidinepropanamide, N-[(3,5-bis(trifluoromethyl)phenyl)methyl]- β -(4-fluorophenyl)-N-methyl- (CA INDEX NAME)




RN 645379-90-4 CAPLUS
CN 4-Piperidinepropanamide, N-[(3,5-dichlorophenyl)methyl]- β -(4-fluorophenyl)-N-methyl- (CA INDEX NAME)



RN 645379-93-7 CAPLUS
CN 4-Piperidinepropanamide, N-[1-(3,5-dichlorophenyl)ethyl]- β -(4-fluorophenyl)-N-methyl- (CA INDEX NAME)


L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 645380-71-8 CAPLUS
CN 4-Piperidinepropanamide, N-[(3,5-dibromophenyl)methyl]- β -(3,4-dichlorophenyl)-4-fluoro-N-methyl-, (β R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 645380-73-0 CAPLUS
CN 4-Piperidinepropanamide, N-[(3,5-dibromophenyl)methyl]- β -(3,4-dichlorophenyl)-4-fluoro-N-methyl-, (β S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 645379-89-1P, N-[3,5-Bis(trifluoromethyl)benzyl]-3-(4-fluorophenyl)-N-methyl-3-piperidin-4-ylpropionamide 645379-90-4P, N-(3,5-Dichlorobenzyl)-3-(4-fluorophenyl)-N-methyl-3-piperidin-4-ylpropionamide 645379-93-7P, N-[1-(3,5-Dichlorophenyl)ethyl]-3-


L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 645379-99-3 CAPLUS
CN 4-Piperidinepropanamide, N-[(3,5-dichlorophenyl)methyl]-4-fluoro- β -(4-fluorophenyl)-N-methyl- (CA INDEX NAME)




RN 645380-06-9 CAPLUS
CN 4-Piperidinepropanamide, N-[(3,5-bis(trifluoromethyl)phenyl)methyl]- β -(4-fluorophenyl)-1-(2-methoxyethyl)-N-methyl- (CA INDEX NAME)



RN 645380-65-0 CAPLUS
CN 4-Piperidinepropanamide, N-[(3,5-dibromophenyl)methyl]-4-fluoro- β -(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


11/03/2008,10521159II.trn

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl


RN 645381-06-2 CAPLUS
CN 3-Piperidinepropanamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-fluoro- β -(4-fluorophenyl)-N-methyl- (CA INDEX NAME)




IT 645379-98-2P, N-[1-(3,5-Dichlorophenyl)ethyl]-3-(4-fluorophenyl)-N-methyl-3-[1-(2-methoxyethyl)piperidin-4-yl]propionamide
645380-00-3P, N-(3,5-Dichlorobenzyl)-3-(4-fluorophenyl)-3-(4-fluoropiperidin-4-yl)-N-methylpropionamide hydrochloride
645380-05-8P, N-[3,5-Bis(trifluoromethyl)benzyl]-3-(4-fluorophenyl)-N-methyl-3-piperidin-4-ylpropionamide hydrochloride
645380-07-0P, N-[[3,5-Bis(trifluoromethyl)phenyl]methyl]-3-(4-fluorophenyl)-N-methyl-3-[1-(2-methoxyethyl)-4-piperidinyl]propionamide hydrochloride 645380-12-7P,

N-[1-[3,5-Bis(trifluoromethyl)phenyl]-1-methylethyl]-3-(4-fluorophenyl)-3-(4-piperidinyl)propionamide 645380-13-8P, N-[1-[3,5-Bis(trifluoromethyl)phenyl]-1-methylethyl]-3-(4-fluorophenyl)-N-methyl-3-(4-piperidinyl)propionamide 645380-15-0P, N-[[3-Bromo-4-(methoxy)phenyl]methyl]-3-(4-fluorophenyl)-N-methyl-3-(4-piperidinyl)propionamide 645380-17-2P, N-[[3,5-Dimethylphenyl]methyl]-3-(4-fluorophenyl)-N-methyl-3-(4-piperidinyl)propionamide 645380-19-4P, N-[[3,4-Dibromophenyl]methyl]-3-(4-fluorophenyl)-N-methyl-3-(4-piperidinyl)propionamide 645380-21-8P, N-[[3-Fluoro-2-methylphenyl]methyl]-3-(4-fluorophenyl)-N-methyl-3-(4-

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 645380-00-3 CAPLUS
CN 4-Piperidinepropanamide, N-[[3,5-dichlorophenyl]methyl]-4-fluoro- β -(4-fluorophenyl)-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 645380-05-8 CAPLUS
CN 4-Piperidinepropanamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]- β -(4-fluorophenyl)-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 645380-07-0 CAPLUS
CN 4-Piperidinepropanamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]- β -(4-fluorophenyl)-1-(2-methoxyethyl)-N-methyl-, monohydrochloride (9CI)

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

piperidinyl]propionamide 645380-23-0P, N-[[2-Chloro-3-(trifluoromethyl)phenyl]methyl]-3-(4-fluorophenyl)-N-methyl-3-(4-piperidinyl)propionamide 645380-27-4P 645380-31-0P
645380-35-4P 645380-39-8P 645380-45-6P
645380-47-8P 645380-51-4P 645380-54-7P
645380-57-0P 645380-61-6P 645380-63-8P,
N-[(3,5-Dibromophenyl)methyl]-3-(4-fluoro-2-methylphenyl)-3-(4-fluoro-4-piperidinyl)-N-methylpropionamide 645380-79-6P
645380-81-0P 645380-87-6P 645380-89-8P
645381-00-6P, N-[[3,5-Bis(trifluoromethyl)phenyl]methyl]-3-(4-fluoro-2-methylphenyl)-N-methyl-3-(1,2,3,6-tetrahydro-4-pyridinyl)propionamide 645381-02-8P 645381-04-0P
645381-05-1P, N-[[3,5-Bis(trifluoromethyl)phenyl]methyl]-3-(4-fluorophenyl)-N-methyl-3-(3-pyrrolidinyl)propionamide 645381-07-3P
645381-09-5P 645381-11-9P 645381-13-1P
645381-15-3P 645381-16-4P, N-[[3,5-Bis(trifluoromethyl)phenyl]methyl]-3-(4-fluorophenyl)-N-methyl-3-(3-piperidinyl)propionamide 645381-18-6P, N-[[3,5-Bis(trifluoromethyl)phenyl]methyl]-3-(4-fluorophenyl)-N-methyl-3-(4-pyridinyl)propionamide 645381-19-7P, N-[1-[3,5-Bis(trifluoromethyl)phenyl]ethyl]-3-(4-fluorophenyl)-N-methyl-3-(4-piperidinyl)propanamide 645381-20-0P, N-[[1-[3,5-Bis(trifluoromethyl)phenyl]ethyl]-3-(4-fluorophenyl)-3-(4-fluoro-4-piperidinyl)-N-methylpropionamide 645381-21-1P,
N-[(3,5-Dibromophenyl)methyl]-3-(4-fluoro-4-piperidinyl)-N-methylpropionamide 645381-22-2P,
N-[[1-[3,5-Bis(trifluoromethyl)phenyl]ethyl]-3-(2,4-dichlorophenyl)-3-(4-fluoro-4-piperidinyl)-N-methylpropionamide 645381-23-3P,

N-[1-[3,5-Bis(trifluoromethyl)phenyl]ethyl]-3-(4-fluoro-2-methylphenyl)-3-(4-fluoro-4-piperidinyl)-N-methylpropionamide 645381-24-4P,
N-[(3,5-Dibromophenyl)methyl]-3-(3,4-dichlorophenyl)-3-(4-fluoro-4-piperidinyl)-N-methylpropionamide 645381-25-5P,

N-[[3,5-Bis(trifluoromethyl)phenyl]methyl]-3-(4-fluorophenyl)-3-(4-fluoro-4-piperidinyl)-N-methylpropionamide 645381-26-6P,
3-(4-Chlorophenyl)-N-[[3,5-dibromophenyl]methyl]-3-(4-fluoro-4-piperidinyl)-N-methylpropionamide 645381-28-8P
645381-29-9P, N-[[1-[3,5-Bis(trifluoromethyl)phenyl]ethyl]-3-(4-fluorophenyl)-N-methyl-3-(2-morpholinyl)propionamide
Rd: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(N-benzyl-3-Ph-3-heterocyclyl-propionamide compds. as tachykinin

and/or

serotonin reuptake inhibitors)


RN 645379-98-2 CAPLUS
CN 4-Piperidinepropanamide, N-[1-[3,5-dichlorophenyl]ethyl]- β -(4-fluorophenyl)-1-(2-methoxyethyl)-N-methyl- (CA INDEX NAME)

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




● HCl

RN 645380-12-7 CAPLUS
CN 4-Piperidinepropanamide, N-[1-[3,5-bis(trifluoromethyl)phenyl]-1-methylethyl]- β -(4-fluorophenyl)- (CA INDEX NAME)




RN 645380-13-8 CAPLUS
CN 4-Piperidinepropanamide, N-[1-[3,5-bis(trifluoromethyl)phenyl]-1-methylethyl]- β -(4-fluorophenyl)-N-methyl- (CA INDEX NAME)




RN 645380-15-0 CAPLUS
CN 4-Piperidinepropanamide, N-[(3-bromo-4-methoxyphenyl)methyl]- β -(4-fluorophenyl)-N-methyl- (CA INDEX NAME)

11/03/2008,10521159II.trn


L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 645380-17-2 CAPLUS
CN 4-Piperidinepropanamide, N-[(3,5-dimethylphenyl)methyl]-β-(4-fluorophenyl)-N-methyl- (CA INDEX NAME)




RN 645380-19-4 CAPLUS
CN 4-Piperidinepropanamide, N-[(3,4-dibromophenyl)methyl]-β-(4-fluorophenyl)-N-methyl- (CA INDEX NAME)



RN 645380-21-8 CAPLUS
CN 4-Piperidinepropanamide, N-[(3-fluoro-2-methylphenyl)methyl]-β-(4-fluorophenyl)-N-methyl- (CA INDEX NAME)




L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 645380-35-4 CAPLUS
CN 4-Piperidinepropanamide, N-[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-fluoro-β-(4-fluorophenyl)-N-methyl-, monohydrochloride, (βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 645380-39-8 CAPLUS
CN 4-Piperidinepropanamide, N-[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-fluoro-β-(4-fluorophenyl)-N-methyl-, monohydrochloride, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 645380-23-0 CAPLUS
CN 4-Piperidinepropanamide, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-β-(4-fluorophenyl)-N-methyl- (CA INDEX NAME)



RN 645380-27-4 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-fluoro-β-(4-fluorophenyl)-N-methyl-, monohydrochloride, (βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 645380-31-0 CAPLUS
CN 4-Piperidinepropanamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-fluoro-β-(4-fluorophenyl)-N-methyl-, monohydrochloride, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 645380-45-6 CAPLUS
CN 4-Piperidinepropanamide, N-[(3,5-dibromophenyl)methyl]-4-fluoro-β-(4-fluorophenyl)-N-methyl-, monohydrochloride, (βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 645380-47-8 CAPLUS
CN 4-Piperidinepropanamide, N-[(3,5-dibromophenyl)methyl]-4-fluoro-β-(4-fluorophenyl)-N-methyl-, monohydrochloride, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/03/2008,10521159II.trn

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 645380-51-4 CAPLUS
CN 4-Piperidinepropanamide,
N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-
beta-(2,4-dichlorophenyl)-4-fluoro-N-methyl-, monohydrochloride,
(betaR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 645380-54-7 CAPLUS
CN 4-Piperidinepropanamide,
N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-
beta-(2,4-dichlorophenyl)-4-fluoro-N-methyl-, monohydrochloride,
(betaS)-(9CI) (CA INDEX NAME)

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
4-fluoro-beta-(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride,
(betaS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645380-63-8 CAPLUS
CN 4-Piperidinepropanamide, N-[(3,5-dibromophenyl)methyl]-4-fluoro-beta-(4-fluoro-2-methylphenyl)-N-methyl- (CA INDEX NAME)




RN 645380-79-6 CAPLUS
CN 4-Piperidinepropanamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-fluoro-beta-(4-fluorophenyl)-N-methyl-, monohydrochloride, (betaR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 645380-57-0 CAPLUS
CN 4-Piperidinepropanamide,
N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-
4-fluoro-beta-(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride,
(betaR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645380-61-6 CAPLUS
CN 4-Piperidinepropanamide,
N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 645380-81-0 CAPLUS
CN 4-Piperidinepropanamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-fluoro-beta-(4-fluorophenyl)-N-methyl-, monohydrochloride, (betaS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645380-87-6 CAPLUS
CN 4-Piperidinepropanamide, beta-(4-chlorophenyl)-N-[(3,5-dibromophenyl)methyl]-4-fluoro-N-methyl-, monohydrochloride, (betaR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/03/2008,10521159II.trn

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 645380-89-8 CAPLUS
CN 4-Piperidinepropanamide, β -(4-chlorophenyl)-N-[(3,5-dibromophenyl)methyl]-4-fluoro-N-methyl-, monohydrochloride, (PS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645381-00-6 CAPLUS
CN 4-Pyridinepropanamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]- β -(4-fluoro-2-methylphenyl)-1,2,3,6-tetrahydro-N-methyl- (CA INDEX NAME)

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 645381-02-8 CAPLUS
CN 4-Pyridinepropanamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]- β -(4-fluoro-2-methylphenyl)-1,2,3,6-tetrahydro-N-methyl-, monohydrochloride, (PR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 645381-04-0 CAPLUS
CN 4-Pyridinepropanamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]- β -(4-fluoro-2-methylphenyl)-1,2,3,6-tetrahydro-N-methyl-, monohydrochloride, (PS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 645381-05-1 CAPLUS
CN 3-Pyrrolidinepropanamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]- β -(4-fluorophenyl)-N-methyl-, monohydrochloride, (PR,2R)- (9CI) (CA INDEX NAME)




RN 645381-07-3 CAPLUS
CN 3-Piperidinepropanamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-fluoro- β -(4-fluorophenyl)-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 645381-09-5 CAPLUS
CN 2-Morpholinepropanamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]- β -(4-fluorophenyl)-N-methyl-, monohydrochloride, (PR,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645381-11-9 CAPLUS
CN 2-Morpholinepropanamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]- β -(4-fluorophenyl)-N-methyl-, monohydrochloride, (PR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

11/03/2008,10521159II.trn


L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 645381-13-1 CAPLUS
CN 2-Morpholinepropanamide,
N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-
β-(4-fluorophenyl)-N-methyl-, monohydrochloride, (βS,2R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




● HCl


RN 645381-15-3 CAPLUS
CN 2-Morpholinepropanamide,
N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-
β-(4-fluorophenyl)-N-methyl-, monohydrochloride, (βS,2S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.


L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 645381-20-0 CAPLUS
CN 4-Piperidinepropanamide, N-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-
fluoro-β-(4-fluorophenyl)-N-methyl- (CA INDEX NAME)




RN 645381-21-1 CAPLUS
CN 4-Piperidinepropanamide, N-[(3,5-dibromophenyl)methyl]-4-fluoro-β-(4-
fluorophenyl)-N-methyl- (CA INDEX NAME)




RN 645381-22-2 CAPLUS
CN 4-Piperidinepropanamide, N-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-
β-(2,4-dichlorophenyl)-4-fluoro-N-methyl- (CA INDEX NAME)

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




● HCl

RN 645381-16-4 CAPLUS
CN 3-Piperidinepropanamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-β-
(4-fluorophenyl)-N-methyl- (CA INDEX NAME)




RN 645381-18-6 CAPLUS
CN 4-Pyridinepropanamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-β-
(4-fluorophenyl)-N-methyl- (CA INDEX NAME)




RN 645381-19-7 CAPLUS
CN 4-Pyridinepropanamide, N-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-
β-(4-fluorophenyl)-N-methyl- (CA INDEX NAME)


L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 645381-23-3 CAPLUS
CN 4-Piperidinepropanamide, N-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-
fluoro-β-(4-fluoro-2-methylphenyl)-N-methyl- (CA INDEX NAME)




RN 645381-24-4 CAPLUS
CN 4-Piperidinepropanamide, N-[(3,5-dibromophenyl)methyl]-β-(3,4-
dichlorophenyl)-4-fluoro-N-methyl- (CA INDEX NAME)




RN 645381-25-5 CAPLUS
CN 4-Piperidinepropanamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-
fluoro-β-(4-fluorophenyl)-N-methyl- (CA INDEX NAME)

11/03/2008,10521159II.trn

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 645381-26-6 CAPLUS
CN 4-Piperidinepropanamide, β -(4-chlorophenyl)-N-[(3,5-dibromophenyl)methyl]-4-fluoro-N-methyl- (CA INDEX NAME)



RN 645381-28-8 CAPLUS
CN 4-Pyridinepropanamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]- β -(4-fluoro-2-methylphenyl)-1,2,3,6-tetrahydro-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 645381-29-9 CAPLUS


L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

645378-69-4P, 1,1-Dimethylethyl 4-[(1R)-3-[[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-4-fluoro-1-piperidinecarboxylate 645378-71-8P, 1,1-Dimethylethyl
4-[(1S)-3-[[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-4-fluoro-1-piperidinecarboxylate 645378-73-0P, 1,1-Dimethylethyl
4-[(1R)-3-[[[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-4-fluoro-1-piperidinecarboxylate 645378-75-2P, 1,1-Dimethylethyl 4-[(1S)-3-[[[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-4-fluoro-1-piperidinecarboxylate 645378-83-2P, 1,1-Dimethylethyl 4-[(1S)-3-[[[(3,5-dibromophenyl)methyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-4-fluoro-1-piperidinecarboxylate 645378-98-9P, 1,1-Dimethylethyl 4-[(1R)-3-[[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-(2,4-dichlorophenyl)-3-oxopropyl]-4-fluoro-1-piperidinecarboxylate 645379-00-6P, 1,1-Dimethylethyl
4-[(1S)-3-[[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-(2,4-dichlorophenyl)-3-oxopropyl]-4-fluoro-1-piperidinecarboxylate 645379-08-4P, 1,1-Dimethylethyl
4-[(1R)-3-[[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-(4-fluoro-2-methylphenyl)-3-oxopropyl]-4-fluoro-1-piperidinecarboxylate 645379-10-8P, 1,1-Dimethylethyl 4-[(1S)-3-[[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-(4-fluoro-2-methylphenyl)-3-oxopropyl]-4-fluoro-1-piperidinecarboxylate 645379-12-0P, 1,1-Dimethylethyl 4-[(1S)-3-[[[(3,5-dibromophenyl)methyl] (methyl)amino]-1-(4-fluoro-2-methylphenyl)-3-oxopropyl]-4-fluoro-1-piperidinecarboxylate 645379-26-6P, 1,1-Dimethylethyl 4-[(1S)-3-[[[(3,5-dibromophenyl)methyl] (methyl)amino]-1-(3,4-dichlorophenyl)-3-oxopropyl]-4-fluoro-1-piperidinecarboxylate 645379-28-8P, 1,1-Dimethylethyl 4-[(1S)-3-[[[(3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-4-fluoro-1-piperidinecarboxylate 645379-36-8P, 1,1-Dimethylethyl 4-[(1R)-3-[[[(3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-4-fluoro-1-piperidinecarboxylate 645379-64-2P, 1,1-Dimethylethyl
4-[(1S)-3-[[[(3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-(4-fluoro-2-methylphenyl)-3-oxopropyl]-3,6-dihydro-1(2H)-pyridinecarboxylate 645379-65-3P, 1,1-Dimethylethyl 4-[(1R)-3-[[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-(4-fluoro-2-methylphenyl)-3-oxopropyl]-3,6-dihydro-1(2H)-pyridinecarboxylate 645379-66-4P, 1,1-Dimethylethyl 4-[(1S)-3-[[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-(4-fluoro-2-methylphenyl)-3-oxopropyl]-3,6-dihydro-1(2H)-pyridinecarboxylate 645379-69-7P, 1,1-Dimethylethyl 3-[(1S)-3-[[[(3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-1-pyrrolidinecarboxylate 645379-72-2P, 1,1-Dimethylethyl
3-[(1S)-3-[[[(3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-3-fluoro-1-piperidinecarboxylate 645379-79-9P, (2R)-4-(tert-Butoxycarbonyl)-2-[(1R)-3-[[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]morpholine 645379-80-2P, (2R)-4-(tert-Butoxycarbonyl)-

2-[(1S)-3-[[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CN 2-Morpholinepropanamide, N-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]- β -(4-fluorophenyl)-N-methyl- (CA INDEX NAME)




IT 645378-27-4P, 4-[2-[[[3,5-Bis(trifluoromethyl)benzyl] (methyl)carbamoyl]-1-(4-fluorophenyl)ethyl]piperidine-1-carboxylic acid tert-butyl ester

645378-29-6P, 4-[2-[[[3,5-Dichlorobenzyl] (methyl)carbamoyl]-1-(4-fluorophenyl)ethyl]piperidine-1-carboxylic acid tert-butyl ester 645378-41-2P, 4-[2-[[[1-(3,5-Dichlorophenyl)ethyl]methylcarbamoyl]-1-(4-fluorophenyl)ethyl]piperidine-1-carboxylic acid tert-butyl ester 645378-51-4P, 4-[2-[[[3,5-Dichlorobenzyl] (methyl)carbamoyl]-1-(4-fluorophenyl)ethyl]-4-fluoropiperidine-1-carboxylic acid tert-butyl ester 645378-52-5P, 1,1-Dimethylethyl 4-[(1R)-3-[[[(R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-1-piperidinecarboxylate 645378-53-6P, 1,1-Dimethylethyl
4-[(1S)-3-[[[(R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-1-piperidinecarboxylate 645378-54-7P, 1,1-Dimethylethyl 4-[(1S)-3-[[[(S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-1-piperidinecarboxylate 645378-55-8P, 1,1-Dimethylethyl 4-[(1S)-3-[[[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-1-piperidinecarboxylate 645378-56-9P, 1,1-Dimethylethyl 4-[(1S)-3-[[[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-1-piperidinecarboxylate 645378-57-0P, 1,1-Dimethylethyl
4-[3-[[[(3-bromo-4-(methoxy)phenyl)methyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-1-piperidinecarboxylate 645378-59-2P, 1,1-Dimethylethyl 4-[3-[[[(3,5-dimethylphenyl)methyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-1-piperidinecarboxylate 645378-60-5P, 1,1-Dimethylethyl
4-[3-[[[(3,4-dibromophenyl)methyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-1-piperidinecarboxylate 645378-62-7P, 1,1-Dimethylethyl
4-[3-[[[(3-fluoro-2-methylphenyl)methyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-1-piperidinecarboxylate 645378-65-0P, 1,1-Dimethylethyl
4-[3-[[[(2-chloro-3-(trifluoromethyl)phenyl)methyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-1-piperidinecarboxylate


645378-56-9P, 1,1-Dimethylethyl 4-[3-[[[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-1-piperidinecarboxylate 645378-57-0P, 1,1-Dimethylethyl
4-[3-[[[(3-bromo-4-(methoxy)phenyl)methyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-1-piperidinecarboxylate 645378-59-2P, 1,1-Dimethylethyl 4-[3-[[[(3,5-dimethylphenyl)methyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-1-piperidinecarboxylate 645378-60-5P, 1,1-Dimethylethyl
4-[3-[[[(3,4-dibromophenyl)methyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-1-piperidinecarboxylate 645378-62-7P, 1,1-Dimethylethyl
4-[3-[[[(3-fluoro-2-methylphenyl)methyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-1-piperidinecarboxylate 645378-65-0P, 1,1-Dimethylethyl
4-[3-[[[(2-chloro-3-(trifluoromethyl)phenyl)methyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-1-piperidinecarboxylate

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

(4-fluorophenyl)-3-oxopropyl]morpholine 645379-81-3P, (2S)-4-(tert-Butoxycarbonyl)-2-[(1R)-3-[[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]morpholine 645379-82-4P, (2S)-4-(tert-Butoxycarbonyl)-2-[(1S)-3-[[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]morpholine 645379-86-8P, 1,1-Dimethylethyl
3-[3-[[[(3,5-bis(trifluoromethyl)phenyl]ethyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-1-piperidinecarboxylate
Rt: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(N-benzyl-3-Ph-3-heterocyclyl-propionamide compds. as tachykinin and/or serotonin reuptake inhibitors)
RN 645378-27-4 CAPLUS
CN 1-Piperidinecarboxylic acid,
4-[3-[[[(3,5-bis(trifluoromethyl)phenyl)methyl] (methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 645378-29-6 CAPLUS
CN 1-Piperidinecarboxylic acid,
4-[3-[[[(3,5-dichlorophenyl)methyl]methylenamino]-1-(4-fluorophenyl)-3-oxopropyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 645378-41-2 CAPLUS
CN 1-Piperidinecarboxylic acid,
4-[3-[[[(3,5-dichlorophenyl)ethyl]methylenamino]-1-(4-fluorophenyl)-3-oxopropyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

11/03/2008,10521159II.trn

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 645378-51-4 CAPLUS
CN 1-Piperidinecarboxylic acid,
4-[3-[[3,5-dichlorophenyl)methyl]methylamino
]-1-(4-fluorophenyl)-3-oxopropyl]-4-fluoro-, 1,1-dimethylethyl ester (CA
INDEX NAME)



RN 645378-52-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(1R)-3-[(1R)-1-[3,5-
bis(trifluoromethyl)phenyl]ethyl]methylamino]-1-(4-fluorophenyl)-3-
oxopropyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 645378-53-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(1S)-3-[(1R)-1-[3,5-
bis(trifluoromethyl)phenyl]ethyl]methylamino]-1-(4-fluorophenyl)-3-
oxopropyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.




RN 645378-54-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(1S)-3-[(1S)-1-[3,5-
bis(trifluoromethyl)phenyl]ethyl]methylamino]-1-(4-fluorophenyl)-3-
oxopropyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.


L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 645378-55-8 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[3-[[1-[3,5-bis(trifluoromethyl)phenyl]-1-
methylethyl]amino]-1-(4-fluorophenyl)-3-oxopropyl]-, 1,1-dimethylethyl
ester (CA INDEX NAME)




RN 645378-56-9 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[3-[[1-[3,5-bis(trifluoromethyl)phenyl]-1-
methylethyl]methylamino]-1-(4-fluorophenyl)-3-oxopropyl]-, 1,1-dimethylethyl
ester (CA INDEX NAME)




RN 645378-57-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[3-[[3-bromo-4-


L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
methoxyphenyl)methyl]methylamino]-1-(4-fluorophenyl)-3-oxopropyl]-,
1,1-dimethylethyl ester (CA INDEX NAME)



RN 645378-59-2 CAPLUS
CN 1-Piperidinecarboxylic acid,
4-[3-[[3,5-dimethylphenyl)methyl]methylamino
]-1-(4-fluorophenyl)-3-oxopropyl]-, 1,1-dimethylethyl ester (CA INDEX
NAME)




RN 645378-60-5 CAPLUS
CN 1-Piperidinecarboxylic acid,
4-[3-[[3,4-dibromophenyl)methyl]methylamino]-
1-(4-fluorophenyl)-3-oxopropyl]-, 1,1-dimethylethyl ester (CA INDEX
NAME)




RN 645378-62-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[3-[[3-fluoro-2-
methylphenyl)methyl]methylamino]-1-(4-fluorophenyl)-3-oxopropyl]-,
1,1-dimethylethyl ester (CA INDEX NAME)

11/03/2008,10521159II.trn

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 645378-65-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl]methylamino]-1-(4-fluorophenyl)-3-oxopropyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 645378-69-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(1R)-3-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]methylamino]-1-(4-fluorophenyl)-3-oxopropyl]-4-fluoro-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
Absolute stereochemistry.



RN 645378-83-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[3-[[[3,5-dibromophenyl]methyl]methylamino]-1-(4-fluorophenyl)-3-oxopropyl]-4-fluoro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 645378-98-9 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(1R)-3-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]methylamino]-1-(2,4-dichlorophenyl)-3-oxopropyl]-4-fluoro-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 645378-71-8 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(1S)-3-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]methylamino]-1-(4-fluorophenyl)-3-oxopropyl]-4-fluoro-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 645378-73-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(1R)-3-[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]methylamino]-1-(4-fluorophenyl)-3-oxopropyl]-4-fluoro-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 645378-75-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(1S)-3-[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]methylamino]-1-(4-fluorophenyl)-3-oxopropyl]-4-fluoro-, 1,1-dimethylethyl ester (CA INDEX NAME)

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 645379-00-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(1S)-3-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]methylamino]-1-(2,4-dichlorophenyl)-3-oxopropyl]-4-fluoro-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 645379-08-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(1R)-3-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]methylamino]-1-(4-fluoro-2-methylphenyl)-3-oxopropyl]-4-fluoro-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.


11/03/2008,10521159II.trn

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 645379-10-8 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(1S)-3-[[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]methylamino]-1-(4-fluoro-2-methylphenyl)-3-oxopropyl]-4-fluoro-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 645379-12-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[3-[[[(3,5-dibromophenyl)methyl]methylamino]-1-(4-fluoro-2-methylphenyl)-3-oxopropyl]-4-fluoro-, 1,1-dimethylethyl ester (CA INDEX NAME)

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 645379-64-2 CAPLUS
CN 1(2H)-Pyridinecarboxylic acid, 4-[[3-[[[(3,5-bis(trifluoromethyl)phenyl)methyl]methylamino]-1-(4-fluoro-2-methylphenyl)-3-oxopropyl]-3,6-dihydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 645379-65-3 CAPLUS
CN 1(2H)-Pyridinecarboxylic acid, 4-[(1R)-3-[[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]methylamino]-1-(4-fluoro-2-methylphenyl)-3-oxopropyl]-3,6-dihydro-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.




L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 645379-26-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[3-[[[(3,5-dibromophenyl)methyl]methylamino]-1-(3,4-dichlorophenyl)-3-oxopropyl]-4-fluoro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 645379-28-8 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[3-[[[(3,5-bis(trifluoromethyl)phenyl)methyl]methylamino]-1-(4-fluorophenyl)-3-oxopropyl]-4-fluoro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 645379-36-8 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[1-(4-chlorophenyl)-3-[[[(3,5-dibromophenyl)methyl]methylamino]-3-oxopropyl]-4-fluoro-, 1,1-dimethylethyl ester (CA INDEX NAME)


L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 645379-66-4 CAPLUS
CN 1(2H)-Pyridinecarboxylic acid, 4-[(1S)-3-[[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]methylamino]-1-(4-fluoro-2-methylphenyl)-3-oxopropyl]-3,6-dihydro-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 645379-69-7 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[3-[[[(3,5-bis(trifluoromethyl)phenyl)methyl]methylamino]-1-(4-fluorophenyl)-3-oxopropyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




11/03/2008,10521159II.trn

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 645379-72-2 CAPLUS
CN 1-Piperidinecarboxylic acid,
3-[3-[[[3,5-bis(trifluoromethyl)phenyl]methyl
[methylamino]-1-(4-fluorophenyl)-3-oxopropyl]-3-fluoro-,
1,1-dimethylethyl
ester (CA INDEX NAME)



RN 645379-79-9 CAPLUS
CN 4-Morpholinecarboxylic acid, 2-[(1R)-3-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]methylamino]-1-(4-fluorophenyl)-3-oxopropyl]-, 1,1-dimethylethyl ester, (2R)- (CA INDEX NAME)


Absolute stereochemistry.




RN 645379-80-2 CAPLUS
CN 4-Morpholinecarboxylic acid, 2-[(1S)-3-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]methylamino]-1-(4-fluorophenyl)-3-oxopropyl]-, 1,1-dimethylethyl ester, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 645379-86-8 CAPLUS
CN 1-Piperidinecarboxylic acid,
3-[3-[[[3,5-bis(trifluoromethyl)phenyl]methyl
[methylamino]-1-(4-fluorophenyl)-3-oxopropyl]-, 1,1-dimethylethyl ester
(CA INDEX NAME)




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 645379-81-3 CAPLUS
CN 4-Morpholinecarboxylic acid, 2-[(1R)-3-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]methylamino]-1-(4-fluorophenyl)-3-oxopropyl]-, 1,1-dimethylethyl ester, (2S)- (CA INDEX NAME)



Absolute stereochemistry.



RN 645379-82-4 CAPLUS
CN 4-Morpholinecarboxylic acid, 2-[(1S)-3-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]methylamino]-1-(4-fluorophenyl)-3-oxopropyl]-, 1,1-dimethylethyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

L26 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ED Entered STN: 13 Dec 2002
GI



AB Title compds. I [R1 represents optionally substituted aryl, optionally substituted heteroaryl, R3NH-Ar1-L2- or R3-NH-C(=O)-NH-Ar2-L2-; R3 represents aryl or heteroaryl; Ar1 represents a saturated, partially saturated or fully unsatd. 8- to 10-membered bicyclic ring system containing at least one

heteroatom selected from O, S or N; Ar2 represents aryl, heteroaryl or heteroaryl; L1 represents a linkage, such as an alkylene linkage; L2 represents an alkylene chain linkage; R2 represents hydrogen, halogen, Cl-alkyl or Cl-alkoxy; and Y is carboxy or an acid bioisostere; but excluding compds. where an oxygen, nitrogen or sulfur atom is attached directly to a carbon carbon multiple bond of an alkenylene or alkynylene residue] and the corresponding N-oxides and ester prodrugs thereof, and the pharmaceutically acceptable salts and solvates of such compds., and the N-oxides and ester prodrugs thereof, are prepared and disclosed as antiinflammatory agents. Thus, II was prepared by hydrolysis of 3-((4-methyl-2-o-tolylaminobenzoxazol-6-yl)-acetyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)-butanoic acid Et ester (preparation given).

In adhesion assays, particular compds. of the invention possessed IC50 values in the range of 77 nM to 100 µM in anal. with both fibronectin and VCAM-1. Such compds. have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4(α4β1).

ACCESSION NUMBER: 2002:946114 CAPLUS
DOCUMENT NUMBER: 138:24648
TITLE: Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases
INVENTOR(S): Fenton, Garry; Harris, Neil Victor

11/03/2008,10521159II.trn


L26 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 PATENT ASSIGNEE(S): Aventis Pharma Limited, UK
 SOURCE: PCT Int. Appl., 77 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002098426	A1	20021212	WO 2002-GB2517	20020605
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SE, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2449402	A1	20021212	CA 2002-2449402	20020605
AU 2002302783	A1	20021216	AU 2002-302783	20020605
EP 1392306	A1	20040303	EP 2002-730462	20020605
EP 1392306	B1	20080116		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005500276	T	20050106	JP 2003-501465	20020605
MX 2003PA09660	A	20040402	MX 2003-PA9660	20031022
US 2004122047	A1	20040624	US 2003-715662	20031118
US 7211586	B2	20070501		
PRIORITY APPLN. INFO.:			GB 2001-13708	A 20010606
			US 2001-311502P	P 20010810
			WO 2002-GB2517	W 20020605

OTHER SOURCE(S): MARPAT 138:24648
 IT 477951-14-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of tetrahydroisoquinolines as antiinflammatory agents)
 RN 477951-14-7 CAPLUS
 CN 7-Isoquinolinepropanamide, α -amino-1,2,3,4-tetrahydro-N-[(1S)-1-phenylethyl]- β -4-pyridinyl- (CA INDEX NAME)


Absolute stereochemistry.

L26 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L26 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 ED Entered STN: 22 Nov 2002
 GI




I

AB A new aza analog of episopicropodophyllin (the C-3 epimer of podophyllotoxin) I has been synthesized exploiting two original strategic steps. Rings A/B and E are entered at an early stage via a cationic benzhydrylation process. A palladium-catalyzed pseudo-domino (Pd-PDOM) intramol. process generates rings C/D in a single synthetic operation.
 ACCESSION NUMBER: 2002:884222 CAPLUS
 DOCUMENT NUMBER: 138:122489
 TITLE: An Episopicropodophyllin Aza Analogue via Palladium-Catalyzed Pseudo-Domino Cyclization
 AUTHOR(S): Poli, Giovanni; Giambastiani, Giuliano
 CORPORATE SOURCE: UMR 7611 CNRS, Universite Pierre et Marie Curie, Paris, F-75252, Fr.
 SOURCE: Journal of Organic Chemistry (2002), 67(26), 9456-9459
 CODEN: JOCEAH; ISSN: 0022-3263
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 138:122489
 IT 489395-99-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of (±)-demethoxy episopicropodophyllin N-benzyl lactam via palladium-catalyzed pseudo-domino cyclization)
 RN 489395-99-5 CAPLUS
 CN 1,3-Benzodioxole-5-propanoic acid, α -[[[(2E)-4-(acetyloxy)-2-butenyl](phenylmethyl)amino]carbonyl]-6-bromo- β -phenyl-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.


L26 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

11/03/2008,10521159II.trn

L26 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ED Entered STN: 02 Jan 1998
GI



AB Cyclic amides such as I are prepared. Thus, I was prepared in 2 steps starting from 3-amino-3-(3-ethoxy-4-methoxyphenyl)propionic acid and phthalaldehyde.

ACCESSION NUMBER: 1998:1310 CAPLUS
DOCUMENT NUMBER: 128:75298
TITLE: Cyclic amides
INVENTOR(S): Muller, George W.
PATENT ASSIGNEE(S): Celgene Corp., USA
SOURCE: U.S., 25 pp., Cont.-in-part of U.S. 5,605,914.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5698579	A	19971216	US 1996-703708	19960827
US 5463063	A	19951031	US 1993-140237	19931020
US 5605914	A	19970225	US 1994-258587	19940610
CA 2531868	A1	19950112	CA 1994-2531868	19940701
EP 1004580	A2	20000531	EP 2000-200491	19940701
EP 1004580	A3	20021002		
EP 1004580	B1	20061220		


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE EP 1004581 A2 20000531 EP 2000-200492 19940701
EP 1004581 A3 20020814
EP 1004581 B1 20040922

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE EP 1004572 A2 20000531 EP 2000-200498 19940701
EP 1004572 A3 20021002
EP 1004572 B1 20060308

L26 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)





L26 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE EP 1477486 A2 20041117 EP 2004-77075 19940701
EP 1477486 A3 20041215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE US 5877200 A 19990302 US 1997-920715 19970829
US 6075041 A 20000613 US 1998-158612 19980922
US 6200987 B1 20010313 US 2000-547085 20000411
US 2003144325 A1 20030731 US 2003-337602 20030106
US 7119106 B2 20061010
US 2006160854 A1 20060720 US 2005-280333 20051117
JP 2006131647 A 20060525 JP 2006-39629 20060216
JP 2006169261 A 20060629 JP 2006-39624 20060216
JP 2006188529 A 20060720 JP 2006-39633 20060216
JP 2006188530 A 20060720 JP 2006-39637 20060216
US 2006178402 A1 20060810 US 2006-401862 20060412
US 2006183910 A1 20060817 US 2006-401858 20060412
PRIORITY APPLN. INFO.: US 1993-87510 B2 19930702

US 1993-140237	A2	19931020
US 1994-258587	A2	19940610
CA 1994-2166315	A3	19940701
EP 1994-921439	A3	19940701
EP 2000-200492	A3	19940701
JP 1995-503648	A3	19940701
US 1996-703708	A3	19960827
US 1997-920715	A3	19970829
US 1998-158612	A3	19980922
US 1999-230389	A3	19990507
US 2000-543809	A1	20000406
US 2001-781179	A1	20010212
US 2003-337602	A3	20030106

OTHER SOURCE(S): MARPAT 128:75298
IT 167887-06-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(cyclic amides as potential tumor necrosis factor inhibitors)
RN 167887-06-1 CAPLUS
CN 2H-Isindole-2-propanamide, β -(3,4-dimethoxyphenyl)-1,3-dihydro-1,3-dioxo-N-(phenylmethyl)- (CA INDEX NAME)

L26 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ED Entered STN: 13 Mar 1997
GI



AB Cyclic imides, such as I [R5 = H, NO2, CN, CF3, CO2Et, CO2Me, CO2Pr, Ac, CONH2, AcO, CO2H, OH, NH2, alkyl, alkoxy, halo; R7 = pyridyl, substituted Ph, (un)substituted benzyl, naphthyl, benzyloxy, imidazol-4-ylmethyl; R12 = amino, OH, ester; n = 0-3], are inhibitors of tumor necrosis factor α and can be used to combat cachexia, endotoxic shock, and retrovirus replication. Thus, I (R5 = H, R7 = 4-MeOC6H4, R12 = NH2, n = 1) was prepared from 3-(4-MeOC6H4)CH(NH2)CH2CO2H and N-(carboethoxy)phthalimide via amidation of the phthalimidopropionic acid. Also, 2-(2,6-dioxo-3-piperidinyl)-4-azaisindoline-1,3-dione (II) was prepared from L-glutamine and 2,3-pyridinedicarboxylic anhydride via intramol. cyclization of glutaramic acid III.


ACCESSION NUMBER: 1997:169160 CAPLUS
DOCUMENT NUMBER: 126:199454
TITLE: Preparation of cyclic imides as inhibitors of tumor necrosis factor α
INVENTOR(S): Muller, George W.
PATENT ASSIGNEE(S): Celgene Corporation, USA
SOURCE: U.S., 22 pp., Cont.-in-part of U.S. Ser. No. 87,510, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5605914	A	19970225	US 1994-258587	19940610
US 5463063	A	19951031	US 1993-140237	19931020
CA 2531868	A1	19950112	CA 1994-2531868	19940701
EP 1004580	A2	20000531	EP 2000-200491	19940701
EP 1004580	A3	20021002		
EP 1004580	B1	20061220		

L26 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE
EP 1004581 A2 20000531 EP 2000-200492 19940701
EP 1004581 A3 20020814
EP 1004581 B1 20040922
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE
EP 1004572 A2 20000531 EP 2000-200498 19940701
EP 1004572 A3 20021002
EP 1004572 B1 20060308
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE
EP 1477486 A2 20041117 EP 2004-77075 19940701
EP 1477486 A3 20041215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE
US 5698579 A 19971216 US 1996-703708 19960827
US 5877200 A 19990302 US 1997-920715 19970829
US 6075041 A 20000613 US 1998-158612 19980922
US 6200987 B1 20010313 US 2000-547085 20000411
US 2003144325 A1 20030731 US 2003-337602 20030106
US 7119106 B2 20061010
US 2006160854 A1 20060720 US 2005-280333 20051117
JP 2006131647 A 20060525 JP 2006-39629 20060216
JP 2006169261 A 20060629 JP 2006-39624 20060216
JP 2006188529 A 20060720 JP 2006-39633 20060216
JP 2006188530 A 20060720 JP 2006-39637 20060216
US 2006178402 A1 20060810 US 2006-401862 20060412
US 2006183910 A1 20060817 US 2006-401858 20060412
PRIORITY APPLN. INFO.: US 1993-87510 B2 19930702

US 1993-140237 A2 19931020
US 1994-258587 A2 19940610
CA 1994-2166315 A3 19940701
EP 1994-921439 A3 19940701
EP 2000-200492 A3 19940701
JP 1995-503648 A3 19940701
US 1996-703708 A3 19960827
US 1997-920715 A3 19970829
US 1998-158612 A3 19980922
US 1999-230389 A3 19990507
US 2000-543809 A1 20000406
US 2001-781179 A1 20010212

L26 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ED Entered STN: 01 Aug 1996
GI



AB Thalidomide (α -N-phthalimidoglutarimide) has been shown to have a wide range of varied biol. activities, including the ability to inhibit tumor necrosis factor- α (TNF- α) production and its accompanying inflammatory manifestations. The central role of TNF- α as a pro-inflammatory cytokine of the immune response suggests that the drug may have important therapeutic utility in a variety of diseases including acute and chronic infections, auto-immune disorders, and malignancies.


To prepare a family of drugs with increased anti-TNF- α activity, a series of analogs of thalidomide was designed, synthesized, and tested for their ability to inhibit TNF- α release by peripheral blood mononuclear cells in vitro. A series of N-phthaloyl β -amino- β -aryl amides and esters was found to have increased activity in inhibiting TNF- α production. The more potent analogs reported here, compds. (I, R = H, R1

= NH2) and (II, R = NH2, R1 = H) are 400-500 times more active than thalidomide in inhibiting TNF- α production

ACCESSION NUMBER: 1996:452533 CAPLUS
DOCUMENT NUMBER: 125:157753
TITLE: Structural Modifications of Thalidomide Produce
Analogues with Enhanced Tumor Necrosis Factor
Inhibitory Activity
AUTHOR(S): Muller, George W.; Corral, Laura G.; Shire, Mary G.;
Wang, Hua; Moreira, Andre; Kaplan, Gilla; Stirling,
David I.
CORPORATE SOURCE: Celgene Corporation, Warren, NJ, 07059, USA
SOURCE: Journal of Medicinal Chemistry (1996), 39(17),
3238-3240
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 167887-06-1
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological

L26 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
US 2003-337602 A3 20030106


IT 167887-06-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic imides as inhibitors of tumor necrosis factor α)
RN 167887-06-1 CAPLUS
CN 2H-Isoindole-2-propanamide, β -(3,4-dimethoxyphenyl)-1,3-dihydro-1,3-dioxo-N-(phenylmethyl)- (CA INDEX NAME)



L26 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
study, unclassified); THU (Therapeutic use); BIOL (Biological study);


USES
(Uses)
(thalidomide analog prepn. for compds. with enhanced TNF- α inhibitory activity)

RN 167887-06-1 CAPLUS
CN 2H-Isoindole-2-propanamide, β -(3,4-dimethoxyphenyl)-1,3-dihydro-1,3-dioxo-N-(phenylmethyl)- (CA INDEX NAME)



11/03/2008,10521159II.trn

L26 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ED Entered STN: 19 Sep 1995
GI



AB A variety of cyclic imides and certain acyclic analogs and/or precursors are inhibitors of tumor necrosis factor α (no data) and can be used to combat cachexia, endotoxic shock, and retrovirus replication. One subgroup of the compds. is I [R₁ = divalent residue of 3,4-pyridine, pyrrolidine, imidazole, naphthalene, thiophene, or C2-6 alkane (un)substituted by (un)substituted Ph; R₂ = CO, SO₂; n = 1-3]. A typical embodiment from a different subgroup is Me 3-phthalimido-3-(3,4-dimethoxyphenyl)propionate, i.e. II, which was prepared from 3,4-(MeO)2C6H3CH(NH2)CH2CO2H by conversion to the Me ester hydrochloride with SOCl₂ and MeOH (66%) and reaction of this with N-(carboethoxy)phthalimide in the presence of Na₂CO₃ in aqueous MeCN (92%). A

total of 93 synthetic examples and 6 formulations are given.


ACCESSION NUMBER: 1995:797249 CAPLUS
DOCUMENT NUMBER: 123:198617
TITLE: Imides as inhibitors of TNF alpha
INVENTOR(S): Muller, George W.
PATENT ASSIGNEE(S): Celgene Corp., USA
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9501348	A2	19950112	WO 1994-US7411	19940701
WO 9501348	A3	19950309		
W: AU, CA, CZ, FI, HU, JP, KR, NZ, PL, RU, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2166315	A1	19950112	CA 1994-2166315	19940701
CA 2166315	C	20060404		
CA 2531868	A1	19950112	CA 1994-2531868	19940701

L26 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
JP 2006188529 A 20060720 JP 2006-39633 20060216
JP 2006188530 A 20060720 JP 2006-39637 20060216
US 2006178402 A1 20060810 US 2006-401862 20060412
US 2006183910 A1 20060817 US 2006-401859 20060412
PRIORITY APPLN. INFO.: US 1993-87510 A 19930702

CA 1994-2166315	A3	19940701
EP 1994-921439	A3	19940701
EP 2000-200492	A3	19940701
JP 1995-503648	A3	19940701
WO 1994-US7411	W	19940701
US 1996-690258	A1	19960724
US 1996-701494	A1	19960822
US 1997-48278P	P	19970530
WO 1997-US13375	A1	19970724
US 1999-230389	B3	19990507
US 2000-543809	A1	20000406
US 2001-781179	A1	20010212
US 2003-337602	A3	20030106

OTHER SOURCE(S): MARPAT 123:198617
IT 167887-06-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of cyclic imides and analogs as TNF- α inhibitors)
RN 167887-06-1 CAPLUS
CN 2H-Isoindole-2-propanamide, β -(3,4-dimethoxyphenyl)-1,3-dihydro-1,3-dioxo-N-(phenylmethyl)- (CA INDEX NAME)



L26 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
AU 9472167 A 19950124 AU 1994-72167 19940701
AU 687843 B2 19980305
EP 706521 A1 19960417 EP 1994-921439 19940701
EP 706521 B1 20021002
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,

SE JP 09500872 T 19970128 JP 1995-503648 19940701
JP 3971794 B2 20070905
HU 75312 A2 19970528 HU 1996-3 19940701
EP 1004580 A2 20000531 EP 2000-200491 19940701
EP 1004580 A3 20021002
EP 1004580 B1 20061220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,


IE EP 1004581 A2 20000531 EP 2000-200492 19940701
EP 1004581 A3 20020814
EP 1004581 B1 20040922
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE EP 1004572 A2 20000531 EP 2000-200498 19940701
EP 1004572 A3 20021002
EP 1004572 B1 20060308
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE PL 180377 B1 20010131 PL 1994-312386 19940701
RU 2174516 C2 20011010 RU 1996-102001 19940701
AT 225344 T 20021015 AT 1994-921439 19940701
PT 706521 T 20030228 PT 1994-921439 19940701
ES 2184765 T3 20030416 ES 1994-921439 19940701
AT 277036 T 20041015 AT 2000-200492 19940701
EP 1477486 A2 20041117 EP 2004-77075 19940701
EP 1477486 A3 20041215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE CZ 294444 B6 20050112 CZ 2003-663 19940701
PT 1004581 T 20050131 PT 2000-200492 19940701
ES 2226696 T3 20050401 ES 2000-200492 19940701
AT 319678 T 20060315 AT 2000-200498 19940701
PT 1004572 T 20060630 PT 2000-200498 19940701
ES 2258956 T3 20060916 ES 2000-200498 19940701
AT 348809 T 20070115 AT 2000-200491 19940701
ES 2278574 T3 20070816 ES 2000-200491 19940701
FI 9506362 A 19960226 FI 1995-6362 19951229
FI 114984 B1 20050215
US 6476052 B1 20021105 US 2000-633908 20000807
HK 1025769 A1 20050408 HK 2000-104989 20000810
HK 1025765 A1 20060818 HK 2000-104991 20000810
HK 1025770 A1 20070316 HK 2000-104990 20000810
US 2003144325 A1 20030731 US 2003-337602 20030106
US 7119106 B2 20061010
FI 2004000593 A 20040427 FI 2004-593 20040427
US 2006160854 A1 20060720 US 2005-280333 20051117
JP 2006131647 A 20060525 JP 2006-39629 20060216
JP 2006169261 A 20060629 JP 2006-39624 20060216


L26 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ED Entered STN: 23 Jul 1994
AB The errors were not reflected in the abstract or the index entries.
ACCESSION NUMBER: 1994:436097 CAPLUS
DOCUMENT NUMBER: 121:36097
TITLE: Structure-based design of inhibitors of purine nucleoside phosphorylase. 3. 9-Arylmethyl derivatives of 9-deazaquinine substituted on the arylmethyl group.
[Erratum to document cited in CA119(25):271601v]
AUTHOR(S): Erion, Mark D.; Niwas, Shri; Rose, Jerry D.; Ananthan, Subramaniam; Allen, Mark; Secrist, John A., III; Babu, Y. Sudhakar; Bugg, Charles E.; Guida, Wayne C.; et al.
CORPORATE SOURCE: BioCryst Pharm., Inc., Birmingham, AL, 35244, USA
SOURCE: Journal of Medicinal Chemistry (1994), 37(7), 1034
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 151332-16-0P 151332-17-1P
RL: SPN (Synthetic preparation); PREP (Preparation) (intermediate in preparation of purine nucleoside phosphorylase-inhibiting arylmethyldeazaquinines (Erratum))
RN 151332-16-0 CAPLUS
CN 1H-Pyrrolo[3,2-d]pyrimidine-7-propanamide, 2-amino- β -(3-chlorophenyl)-4,5-dihydro-4-oxo-N-(1-phenylethyl)-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)
Absolute stereochemistry.




RN 151332-17-1 CAPLUS
CN 1H-Pyrrolo[3,2-d]pyrimidine-7-propanamide, 2-amino- β -(3-chlorophenyl)-4,5-dihydro-4-oxo-N-(1-phenylethyl)-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)
Absolute stereochemistry.

11/03/2008,10521159II.trn

L26 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L26 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ED Entered STN: 02 Apr 1994
GI



AB RCHR2(CR3R4)nYp(CH2)mX [R = oxopyrrolopyrimidinyl group Q; R1 = H, NH2, OMe; R2 = (substituted) cyclic group optionally containing ≥ 1 heteroatom; R3,R4 = H, alkyl; Y = O, NH; X = cyano, CSNH2, CO2H, NH2, alkoxycarbonyl, etc.; m = 0-4; n = 0-6; p = 0, 1] were prepared, NH2, 3-ClC6H4CH2CH2CO2H (R = Q) was amidated by (R)-(+)-H2NCHMePh and the diastereomers separated and hydrolyzed to give (S)-3-ClC6H4CH2CH2CO2H which had IC50 of 31 and 5.9 μ M at 50 and 1mM phosphate, resp., against purine phosphorylase in vitro.


ACCESSION NUMBER: 1994:164216 CAPLUS
DOCUMENT NUMBER: 120:164216
TITLE: Preparation of (oxopyrrolopyrimidinyl) alkanoates and analogs as purine phosphorylase inhibitors
INVENTOR(S): Niwas, Shri; Secrist, John A., III; Montgomery, John A.
PATENT ASSIGNEE(S): Biocryst Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9321187	A1	19931028	WO 1993-US2841	19930325
W: AU, CA, FI, HU, JP, KR, KZ, NO, RU, UA				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9342766	A	19931118	AU 1993-42766	19930325
EP 638080	A1	19950215	EP 1993-912081	19930325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07507062	T	19950803	JP 1993-518357	19930325
HU 71559	A2	19951228	HU 1994-3021	19930325
FI 9404933	A	19941020	FI 1994-4933	19941020
NO 9403988	A	19941020	NO 1994-3988	19941020
US 5726311	A	19980310	US 1995-475098	19950607
PRIORITY APPLN. INFO.:			US 1992-871441	A 19920421

L26 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
US 1989-442798 B1 19891129
US 1991-701575 A2 19910514
WO 1993-US2841 A 19930325
US 1994-320415 B1 19941003


OTHER SOURCE(S): MARPAT 120:164216
IT 151332-16-OP 151332-17-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of purine phosphorylase inhibitor)
RN 151332-16-0 CAPLUS
CN 1H-Pyrrolo[3,2-d]pyrimidine-7-propanamide, 2-amino- β -(3-chlorophenyl)-4,5-dihydro-4-oxo-N-(1-phenylethyl)-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 151332-17-1 CAPLUS
CN 1H-Pyrrolo[3,2-d]pyrimidine-7-propanamide, 2-amino- β -(3-chlorophenyl)-4,5-dihydro-4-oxo-N-(1-phenylethyl)-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ED Entered STN: 25 Dec 1993
GI



AB X-ray crystallog. and computer-assisted mol. modeling (CAMM) studies aided in the design of a potent series of mammalian purine nucleoside phosphorylase (PNP) inhibitors. Enhanced potency was achieved by designing substituted 9-(arylmethyl)-9-deazaguanine analogs that interact with all three of the binding subsites found for PNP, namely the purine binding site, the hydrophobic pocket, and the phosphate binding site.


The most potent PNP inhibitor prepared, (S)-9-[1-(3-chlorophenyl)-2-carboxyethyl]-9-deazaguanine (I), had an IC50 of 6 nM, whereas the (R)-isomer was 30-fold less potent.

ACCESSION NUMBER: 1993:671601 CAPLUS
DOCUMENT NUMBER: 119:271601
TITLE: Structure-based design of inhibitors of purine nucleoside phosphorylase. 3. 9-Arylmethyl derivatives of 9-deazaguanine substituted on the arylmethyl group
AUTHOR(S): Erion, Mark D.; Niwas, Shri; Rose, Jerry D.; Ananthan, Subramaniam; Allen, Mark; Secrist, John A., III; Babu, Y. Sudhakar; Bugg, Charles E.; Guida, Wayne C.; et al.
CORPORATE SOURCE: BioCryst Pharm., Inc., Birmingham, AL, 35244, USA
SOURCE: Journal of Medicinal Chemistry (1993), 36(24), 3771-83
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 151332-16-OP 151332-17-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(intermediate in preparation of purine nucleoside phosphorylase-inhibiting arylmethyldeazaguanines)
RN 151332-16-0 CAPLUS
CN 1H-Pyrrolo[3,2-d]pyrimidine-7-propanamide, 2-amino- β -(3-chlorophenyl)-4,5-dihydro-4-oxo-N-(1-phenylethyl)-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/03/2008,10521159II.trn

L26 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 151332-17-1 CAPLUS
CN 1H-Pyrrolo[3,2-d]pyrimidine-7-propanamide, 2-amino-β-(3-chlorophenyl)-4,5-dihydro-4-oxo-N-(1-phenylethyl)-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ED Entered STN: 17 Oct 1992
GI



AB Agrochem. fungicides contain maleimides I [R = OR1, NR2R3; R1 = linear or branched C1-5 alkyl, (un)substituted aryl, (un)substituted PhCH2; R2, R3 =

H, linear or branched C1-5 alkyl, (un)substituted Ph, (un)substituted PhCH2, heterocyclyl; X = H, halo, CF3] as active ingredients. Treatment of I (R = OH, X = 4-Cl) (preparation given) with MeOH, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide-HCl salt, and 4-pyrrolidinopyridine in CH2Cl2 at room temperature for 3 h gave 54% I

(R = OMe, X = 4-Cl), which at 500 ppm totally inhibited Pyricularia oryzae infection in rice.


ACCESSION NUMBER: 1992:545301 CAPLUS
DOCUMENT NUMBER: 117:145301
TITLE: Preparation of maleimides as agrochemical fungicides
INVENTOR(S): Niwada, Shinjiro; Fukami, Jiichi; Hashimoto, Masaki; Otsuka, Norio; Fujita, Fumio
PATENT ASSIGNEE(S): Suntory K. K., Japan; Zenkoku Nogyo Kyodo Kumiai Rengokai
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04089478	A	19920323	JP 1990-203825	19900802
PRIORITY APPLN. INFO.:			JP 1990-203825	19900802


OTHER SOURCE(S): MARPAT 117:145301
IT 143438-64-6P 143438-85-1P 143438-86-2P
143438-87-3P 143438-88-4P 143438-89-5P
143438-90-8P 144275-77-4P

L26 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of, as agrochem. fungicide)

RN 143438-64-6 CAPLUS
CN 1H-Pyrrole-1-propanamide, 3,4-dichloro-N-[(4-chlorophenyl)methyl]-2,5-dihydro-2,5-dioxo-β-phenyl- (CA INDEX NAME)




RN 143438-85-1 CAPLUS
CN 1H-Pyrrole-1-propanamide, 3,4-dichloro-2,5-dihydro-2,5-dioxo-β-phenyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 143438-86-2 CAPLUS
CN 1H-Pyrrole-1-propanamide, 3,4-dichloro-2,5-dihydro-N-methyl-2,5-dioxo-β-phenyl-N-(phenylmethyl)- (CA INDEX NAME)

L26 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 143438-87-3 CAPLUS
CN 1H-Pyrrole-1-propanamide, 3,4-dichloro-β-(4-chlorophenyl)-N-[(4-chlorophenyl)methyl]-2,5-dihydro-2,5-dioxo-β-phenyl- (CA INDEX NAME)




RN 143438-88-4 CAPLUS
CN 1H-Pyrrole-1-propanamide, 3,4-dichloro-N-[(4-chlorophenyl)methyl]-2,5-dihydro-2,5-dioxo-β-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)

11/03/2008,10521159II.trn


L26 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 143438-89-5 CAPLUS
CN 1H-Pyrrole-1-propanamide, 3,4-dichloro-N-[(4-chlorophenyl)methyl]-β-(4-fluorophenyl)-2,5-dihydro-2,5-dioxo- (CA INDEX NAME)




L26 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L26 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 143438-90-8 CAPLUS
CN 1H-Pyrrole-1-propanamide, 3,4-dichloro-N-[(4-chlorophenyl)methyl]-β-(3-fluorophenyl)-2,5-dihydro-2,5-dioxo- (CA INDEX NAME)



RN 144275-77-4 CAPLUS
CN 1H-Pyrrole-1-propanamide, 3,4-dichloro-N-[(4-chlorophenyl)methyl]-2,5-dihydro-2,5-dioxo-β-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

L26 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ED Entered STN: 12 May 1984

GI For diagram(s), see printed CA Issue.

AB The reaction of I (R = H, Me, Ph) with NH₂R₁ (R₁ = H, Pr, iso-Pr, Bu, tert-Bu, CH₂Ph) at room temperature in C₆H₆ gave 53-97% of the corresponding

II. II or III were cyclized on heating into the corresponding IV, in 28-64% yields. The ring chain transformation is discussed.

ACCESSION NUMBER: 1971:540580 CAPLUS

DOCUMENT NUMBER: 75:140580

ORIGINAL REFERENCE NO.: 75:22181a,22184a

TITLE: Ring-chain transformation involving the carbonyl group. VII. Reactions of 3-R-4-phenyl-5,3'-spiropthalido-2-furanidones with primary aliphatic amines

AUTHOR(S): Valters, R.; Kipina, A.

CORPORATE SOURCE: Rīzh. Politekh. Inst., Riga, USSR

SOURCE: Latvijas PSR Zinatnu Akademijas Vestis, Kimijas

Serijs

(1971), (2), 200-7

CODEN: LZAKAM; ISSN: 0002-3248

DOCUMENT TYPE: Journal


LANGUAGE: Russian

IT 33879-86-6P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

RN 33879-86-6 CAPLUS

CN 1-Isindolinepropionamide, N,2-dibenzyl-1-hydroxy-3-oxo-β-phenyl-(8CI) (CA INDEX NAME)



11/03/2008,10521159II.trn

L26 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ED Entered STN: 12 May 1984

AB The Wolff rearrangement of 1-phthaloylamino-3-diazo-2-alkanones in the presence of DL-H₂NCHPhCH₂CO₂Et or DL-phenylalanine esters, catalyzed by Ag₂O, or occurring photolytically, yielded β-phthaloylamino-3-phenyl-2-aminopropionyl- amino acid esters, which upon saponification of the ester group and subsequent

hydrazinolysis gave the following H₃N+CHRCHR₁C(O)NHCHR₂(CH₂)_nCO₂- (R = H or Ph, R₁ = H, Me, Et and R₂ = Ph or CH₂Ph, n = 0 or 1).

ACCESSION NUMBER: 1968:487466 CAPLUS

DOCUMENT NUMBER: 69:87466

ORIGINAL REFERENCE NO.: 69:16395a,16398a

TITLE: Synthesis of dipeptides of some β-amino acids via α-diazo ketones

AUTHOR(S): Jugelt, W.; Falck, P.

CORPORATE SOURCE: Humboldt-Univ. Berlin, Berlin, Fed. Rep. Ger.

SOURCE: Journal fuer Praktische Chemie (Leipzig) (1968), 38(1-2), 88-100

CODEN: JPCEAO; ISSN: 0021-8383

DOCUMENT TYPE: Journal

LANGUAGE: German


OTHER SOURCE(S): CASREACT 69:87466

IT 19745-62-1P 19771-62-1P 19776-44-4P

RL: SPN (Synthetic preparation); PREP (Preparation of)


RN 19745-62-1 CAPLUS

CN Hydrocinnamic acid, β-(β-phthalimidohydrocinnamido)- (8CI)
(CA INDEX NAME)



RN 19771-62-1 CAPLUS

CN Hydrocinnamic acid, β-(β-phthalimidohydrocinnamido)-, ethyl ester (8CI) (CA INDEX NAME)




RN 19776-44-4 CAPLUS

CN 2-Isindolinepropionamide, N-(α-methylbenzyl)-1,3-dioxo-β-

L26 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
phenyl- (8CI) (CA INDEX NAME)

(Continued)



11/03/2008,10521159II.trn

=> log h

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

93.13

1243.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-13.60

-48.80

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 12:58:42 ON 25 FEB 2008